Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL681902 | 0.96 | AOC3 (0.32) | AOC3 | |
| SCHEMBL1976327 | 0.96 | AOC3 (0.35) | AOC3 | |
| Hydrochloric Acid SCHEMBL9542269 | 0.92 | AOC3 (0.37) | AOC3 | |
| SCHEMBL125254 | 0.92 | AOC3 (0.33) | AOC3 | |
| SCHEMBL14135238 | 0.88 | AOC3 (0.35) | AOC3 | |
| SCHEMBL13676784 | 0.81 | — | — | |
| SCHEMBL22067833 | 0.81 | HRH4 (0.30) | — | |
| SCHEMBL12345549 | 0.76 | AOC3 (0.34) | AOC3 | |
| SCHEMBL395734 | 0.74 | SLC11A2 (0.35) | AOC3 | |
| SCHEMBL22535956 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Apollo Therapeutics Limited (GB) | 2023-08-10 | — | — | US | disclosed |
| US-9695260-B2 | Method for producing olefin block polymer using plurality of types of transition metal catalysts | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-07-04 | — | — | US | disclosed |
| US-20170107174-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIVERSITE DE LILLE (FR) | 2017-04-20 | — | — | US | disclosed |
| US-9593194-B2 | Method for producing olefin block polymer using group 4 transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-03-14 | — | — | US | disclosed |
| US-20160346256-A1 | AMIDE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2016-12-01 | — | — | US | disclosed |
| US-8871885-B2 | Ethylene-a-olefin copolymer and molded article | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-10-28 | — | — | US | disclosed |
| US-20140296306-A1 | AMIDE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20140275429-A1 | METHOD FOR PRODUCING OLEFIN BLOCK POLYMER USING PLURALITY OF TYPES OF TRANSITION METAL CATALYSTS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-09-18 | — | — | US | disclosed |
| US-8809462-B2 | Ethylene-α-olefin copolymer, molded article, catalyst for copolymerization, and method for producing an ethylene-α-olefin copolymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-08-19 | — | — | US | disclosed |
| US-20140163173-A1 | METHOD FOR PRODUCING OLEFIN BLOCK POLYMER USING GROUP 4 TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-06-12 | — | — | US | disclosed |
| US-6870015-B2 | Catalyst component for addition polymerization, process for producing catalyst for addition polymerization and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-03-22 | — | — | US | disclosed |
| US-20040209767-A1 | Contact product, and catalyst component and catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-10-21 | — | — | US | disclosed |
| US-20040186009-A1 | Catalyst component and catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-09-23 | — | — | US | disclosed |
| US-20030203810-A1 | Catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED | 2003-10-30 | — | — | US | disclosed |
| US-6586356-B2 | Coordination catalyst | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-07-01 | — | — | US | disclosed |
| EP-1300425-A2 | Catalyst component for addition polymerization, process for producing said catalyst and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-04-09 | — | — | EP | disclosed |
| US-20030060579-A1 | Catalyst component for addition polymerization, process for producing catalyst for addition polymerization and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-03-27 | — | — | US | disclosed |
| US-20020143124-A1 | Homogeneous type solid catalyst component or homogeneous type solid catalyst, process for production thereof and process for producing addition polymer with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-10-03 | — | — | US | disclosed |
| US-20010020075-A1 | Catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-09-06 | — | — | US | disclosed |
| EP-1113026-A2 | Catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CSNK1A1, CSNK1D, CSNK2A1 | AOC3 4448/4885 |
| US-20170107174-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | MAPT, PSEN2, SNCA | AOC3 1367/4885 |
| US-20160346256-A1 | AMIDE COMPOUND AND MEDICINAL USE THEREOF | SLC10A2, SLC10A1, SLC5A11 | AOC3 3926/4885 |
| US-20140296306-A1 | AMIDE COMPOUND AND MEDICINAL USE THEREOF | SLC10A2, SLC10A1, SLC5A11 | AOC3 3926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.